PDE1C — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL285263	0.72	16/20
SCHEMBL285264	0.72	16/20
SCHEMBL407938	0.72	16/20
SCHEMBL155132	0.50	14/20
SCHEMBL291618	0.53	12/20
SCHEMBL299992	0.59	11/20
SCHEMBL298932	0.52	11/20
SCHEMBL299743	0.62	10/20
SCHEMBL298595	0.62	10/20
SCHEMBL298757	0.62	10/20
SCHEMBL299367	0.59	10/20
SCHEMBL299935	0.55	10/20
SCHEMBL299164	0.52	10/20
SCHEMBL299194	0.52	10/20
SCHEMBL299001	0.51	10/20
SCHEMBL299557	0.51	10/20
SCHEMBL299352	0.50	10/20
SCHEMBL299383	0.50	10/20
SCHEMBL5537	1.00	9/20
Idoxifene (SCHEMBL19216)	1.00	9/20

Clinical trials — most relevant to PDE1C by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Switching of Sildenafil to Riociguat in CTEPH Patients	PHASE4	RECRUITING
REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs	PHASE4	COMPLETED
Bosentan in Treatment of Pulmonary Arterial Hypertension	PHASE4	COMPLETED
Therapeutic Effect of Sildenafil in Patients With Coronary Vasospasm	PHASE3	WITHDRAWN
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia	PHASE2/PHASE3	UNKNOWN
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension	PHASE3	COMPLETED
Chronic Sildenafil Treatment in Heart Failure	PHASE3	COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension	PHASE3	COMPLETED
Genetic Factors of Erectile Dysfunction Degree and Response to Tadalafil Treatment in Patients With Diabetes	PHASE3	RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm	PHASE2	WITHDRAWN
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)	PHASE1/PHASE2	COMPLETED
Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)	PHASE2	RECRUITING
Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial	PHASE2	COMPLETED
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease	PHASE2	COMPLETED
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension	PHASE2	COMPLETED
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals	PHASE1/PHASE2	COMPLETED
Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients	PHASE2	COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals	PHASE1	COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction	PHASE1	COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy	nan	WITHDRAWN
Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice.	nan	UNKNOWN
Endurance Performance at Altitude	nan	COMPLETED
Clinical Study Evaluating the Effect of Losartan	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PDE1C binder may also engage these)

Protein	Name	Similarity
Q64338	—	0.999	Q64338 →
Q63421	—	0.996	Q63421 →
Q61481	—	0.979	Q61481 →
Q01066	—	0.975	Q01066 →
P14100	—	0.972	P14100 →
PDE1A	Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	0.971	landscape →
Q01061	—	0.969	Q01061 →
Q64395	—	0.968	Q64395 →
P32023	—	0.968	P32023 →
Q01065	—	0.968	Q01065 →
PDE1B	Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	0.967	landscape →
PI4KB	Phosphatidylinositol 4-kinase beta	0.967	landscape →
A2APV2	—	0.967	A2APV2 →
Q28C33	—	0.966	Q28C33 →
B0KWC1	—	0.966	B0KWC1 →
B1MTG7	—	0.966	B1MTG7 →
O08561	—	0.966	O08561 →
Q9BWT3	—	0.965	Q9BWT3 →
Q9Z0V1	—	0.965	Q9Z0V1 →
Q9BXB4	—	0.965	Q9BXB4 →
Q62897	—	0.965	Q62897 →
B7YZV4	—	0.965	B7YZV4 →
A4IID4	—	0.965	A4IID4 →
Q69ZT9	—	0.965	Q69ZT9 →
Q07722	—	0.964	Q07722 →
O02810	—	0.964	O02810 →
Q8CI95	—	0.964	Q8CI95 →
Q80TJ7	—	0.964	Q80TJ7 →
B2RQE8	—	0.963	B2RQE8 →
Q6NNF2	—	0.963	Q6NNF2 →